SaniMed Science Group is a global health-tech investment and commercialization firm focused on Biotech, MedTech, TechBio, and AI-enabled healthcare innovations. We invest in and partner with early- and growth-stage companies developing differentiated technologies with clear clinical and regulatory pathways.

Leveraging deep expertise in FDA/NMPA strategy, preclinical and IND-enablement planning, medical device engineering, and cross-border development execution, SaniMed supports portfolio companies in accelerating product readiness and market entry.

Through our international network of hospitals, CRO/CDMOs, research institutes, and industrial partners, SaniMed helps founders reduce development risk, strengthen regulatory positioning, and scale efficiently across the U.S. and Asia. Our mission is to back transformative science and enable global commercialization that delivers meaningful healthcare impact.